The role of hyperbaric oxygenotherapy (HBOT) in the treatment of COVID-19 patients
Sead Žiga, Dejan Andrić, Sanja Jurić Banai, Kristina Franjić, Dragan Vujović, Eva Pleško, Dživo Ljubičić, Nevenka Piskač Živković, Marko Banić
The COVID-19 pandemic has posed a major challenge to modern medicine. Despite significant efforts by the medical and scientific community, at the time of writing, there is still no targeted etiological treatment for acutely ill COVID-19 patients as well as patients with post-COVID syndrome. Hyperbaric oxygen therapy (HBOT) is a medically and scientifically recognized therapeutic procedure in the treatment of a number of acute and chronic conditions in which oxygen deficiency is pathophysiologically primary disorder. Given the several published series of cases that have shown a significant beneficial effect of HBOT in the treatment of patients with COVID-19 infection, and based on decades of experience in the use of HBOT in other fields, the need to conduct quality and well-structured studies arose with the aim to clearly examine the impact of HBOT use in the treatment of COVID-19 patients. According to available sources, nine such studies are being conducted worldwide.The mechanisms of the effect of HBOT in the treatment of COVID-19 patients are based on the correction of hypoxia, attenuation of the inflammatory response and “repayment of oxygen debt” in a short period of time, thus providing a window to aerobic metabolism in deeply hypoxic tissues and important organs.
Dejan Andrić, Dragan Vujović, Dživo Ljubičić, Eva Pleško, Kristina Franjić, Marko Banić, Nevenka Piskač Živković, Sanja Jurić Banai, Sead Žiga